Investigation of factors affectingin vitrodoxorubicin release from PEGylated liposomal doxorubicin for the development ofin vitrorelease testing conditions-Reference-Cited by-同舟云学术

Investigation of factors affectingin vitrodoxorubicin release from PEGylated liposomal doxorubicin for the development ofin vitrorelease testing conditions

Published:2014-08-29 Issue:8 Volume:41 Page:1376-1386
ISSN:0363-9045
Container-title:Drug Development and Industrial Pharmacy
language:en
Short-container-title:Drug Development and Industrial Pharmacy

Author:

Shibata Hiroko,Izutsu Ken-ichi,Yomota Chikako,Okuda Haruhiro,Goda Yukihiro

Publisher

Informa UK Limited

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.3109/03639045.2014.954582

Reference40 articles.

1. Nanomedicines and Nanodiagnostics Come of Age

2. Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science

3. The therapeutic equivalence of complex drugs

4. How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider

5. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Robust Chromatographic Method for Drug Release profiling of liposomal doxorubicin HCl;Journal of Pharmaceutical Sciences;2024-09

2. AmBisome® Formulations for Pediatrics: Stability, Cytotoxicity, and Cost-Effectiveness Studies;Pharmaceutics;2024-03-27

3. Liposomal encapsulation of amoxicillin via microfluidics with subsequent investigation of the significance of PEGylated therapeutics;International Journal of Pharmaceutics;2024-01

4. In vitro evaluation and in vivo efficacy studies of a liposomal doxorubicin-loaded glycyrretinic acid formulation for the treatment of hepatocellular carcinoma;Pharmaceutical Development and Technology;2023-11-08

5. Liposomal Doxorubicin Kinetic Study in an In vitro 2D and 3D Tumor Model for Osteosarcoma in a Perfusion Bioreactor;Pharmaceutical Nanotechnology;2023-10